+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Therapy Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Targeted Therapy Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Targeted Therapy Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6017448
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted Therapy Market grew from USD 67.16 billion in 2024 to USD 72.41 billion in 2025. It is expected to continue growing at a CAGR of 7.53%, reaching USD 103.84 billion by 2030.

Targeted therapy has emerged at the forefront of modern medicine by shifting treatment paradigms from non‐specific cytotoxic approaches to precision‐driven interventions tailored to individual patient biology. Fueled by advances in genomic profiling, molecular diagnostics and an expanding understanding of disease pathways, these therapies achieve higher efficacy and reduced off‐target effects. Collaboration among academia, biotechnology innovators and large‐scale pharmaceutical enterprises has accelerated pipeline diversity, while patient advocacy groups have influenced clinical trial inclusion criteria, ensuring broader representation and more meaningful endpoints. Digital monitoring tools now enhance post‐approval safety management, and lifecycle strategies such as label expansions and combination regimens prolong therapeutic relevance. This executive summary explores the key forces propelling targeted therapy growth, analyzes transformative shifts in the competitive landscape, assesses the cumulative impact of 2025 U.S. tariffs on supply and pricing strategies, and distills insights from segmentation, regional dynamics and leading company initiatives. Finally, it offers actionable recommendations and a compelling call to action for leaders seeking to harness these developments and secure sustainable patient and commercial success.

Transformative Shifts Reshaping the Targeted Therapy Landscape

Over the past decade, the targeted therapy landscape has undergone transformative shifts driven by synergistic advances in science, technology and policy. Breakthroughs in precision medicine have been enabled by AI‐driven target discovery platforms and high‐throughput screening tools. Decentralized clinical trial models and telemedicine have broadened patient access, accelerated recruitment and reduced protocol deviations, while real‐world data integration has strengthened market access submissions. Regulatory agencies are piloting adaptive approval pathways, allowing progressive evidence generation post‐approval and compressing development timelines. Companion diagnostics are now routinely co‐developed, unlocking value‐based pricing strategies that align cost with demonstrated outcomes. Digital therapeutics integration and biomarker‐driven endpoints have redefined competitive dynamics, shifting the traditional blockbuster model toward a mosaic of niche therapies tailored for specific genetic or molecular profiles. Concurrently, manufacturing innovations-such as modular bioprocessing units and continuous flow systems-are enhancing scalability and reducing time to market. Patient‐centric care models incorporating remote monitoring and adherence support reinforce engagement and long‐term retention. These systemic shifts underscore the rise of a multi‐stakeholder ecosystem in which academia, biotech, CROs and big pharma converge to optimize R&D productivity, regulatory agility and commercialization efficacy.

Assessing the 2025 U.S. Tariffs on Targeted Therapies

In January 2025, the United States implemented new tariffs on imported biologics and advanced therapies, introducing additional duty rates on monoclonal antibodies, recombinant proteins and vector-based treatments. This policy change has reverberated across global supply chains, prompting companies to reassess manufacturing footprints and prioritize domestic production to mitigate cost pressures. Lead times for critical active pharmaceutical ingredients have lengthened, driving firms to adjust buffer stock levels and develop contingency sourcing strategies. Pricing negotiations have intensified as payers push back on list price increases, while cross-border collaborations face renegotiated commercial terms. Intellectual property and licensing agreements have been recalibrated to account for shifting trade dynamics, and emerging market manufacturers in Asia and Latin America are exploring preferential trade arrangements to circumvent tariff barriers. Stakeholders have engaged policymakers to seek exemptions for R&D materials and early-stage clinical supplies, highlighting the tension between fostering innovation and protecting domestic industries. Collectively, these developments underscore the importance of a robust risk management framework that balances cost efficiency, regulatory compliance and uninterrupted patient access.

In-Depth Segmentation Analysis Revealing Market Drivers

By dissecting the market across therapy type, one observes portfolios spanning antibody-drug conjugates, biosimilars, cancer vaccines, cell therapies, gene therapies, hormonal therapies, monoclonal antibodies and small molecules. Within the cancer vaccine domain, preventive vaccines focus on immunoprophylaxis, while therapeutic vaccines aim to elicit antitumor responses in established disease. When viewed through the lens of target disease, interventions address cardiology indications-such as atherosclerosis and heart failure-alongside neurology treatments for Alzheimer’s disease and Parkinson’s disease, oncology regimens targeting breast, lung and prostate cancers, and specialized therapies for rare conditions including cystic fibrosis and hemophilia. Evaluating drug type highlights the interplay between branded innovations commanding premium pricing and generic alternatives expanding accessibility. The therapeutic application dimension reveals strategic differentiation across adjuvant, neoadjuvant and second-line paradigms, each informing clinical trial design and reimbursement negotiations. End-user analysis encompasses ambulatory surgical centers, clinics, hospitals and research institutes, illustrating diverse service delivery settings and associated procurement models. Mechanism-based segmentation further refines the landscape, with angiogenesis inhibitors divided into PDGFR tyrosine kinase and VEGFR tyrosine kinase subcategories, complemented by immunomodulators, kinase inhibitors and proteasome inhibitors. This multi-axis segmentation framework illuminates unique adoption drivers, regulatory considerations and commercialization challenges that must inform portfolio prioritization and launch sequencing.

Regional Dynamics Influencing Targeted Therapy Adoption

Across the Americas, robust clinical trial infrastructure and favorable reimbursement policies accelerate uptake of monoclonal antibodies, cell therapies and biosimilars. North American manufacturing hubs adapt to tariff-induced cost pressures by localizing production, implementing lean manufacturing practices and securing critical reagent supplies. Latin American markets showcase growing demand for generics and hormonal therapies as healthcare access expands amidst evolving public-private partnerships. In Europe, Middle East and Africa, regulatory alignment under the European Medicines Agency fosters cross-border registration of cancer vaccines and immunomodulators, although heterogeneous national reimbursement schemes necessitate customized market access strategies. The region’s advanced research networks-from Western Europe’s oncology centers to emerging biotech hubs in the Middle East and Africa-drive early-phase studies in rare disease and neurology. Asia-Pacific demonstrates rapid investment in cell and gene therapy manufacturing capabilities, supported by government-led innovation grants in China, Japan and South Korea. Personalized medicine adoption is accelerating via digital diagnostics platforms and telehealth solutions, while strategic partnerships between global biopharma and local firms catalyze late-stage development and distribution. Regulatory harmonization initiatives aim to streamline dossier submissions, and the integration of real-world evidence reinforces value propositions for payers and regulators. These regional dynamics collectively signal a global shift toward data-driven, patient-centric care models.

Leading Organizations Driving Innovation in Targeted Therapies

Global biopharmaceutical leaders are intensifying efforts across targeted therapy portfolios and strategic collaborations. AbbVie Inc., Amgen Inc. and Bristol Myers Squibb Company are advancing next-generation monoclonal antibodies and cell therapies through partnerships with academic centers. Astellas Pharma Inc. and AstraZeneca PLC pursue kinase inhibitor development, leveraging novel targets to address oncology and immunology indications. Bayer AG and Takeda Pharmaceutical Company Limited focus on expanding biosimilar offerings and enhancing pipeline diversity. BeiGene, Ltd., Gilead Sciences, Inc. and Merck KGaA emphasize cell and gene therapy platforms, aiming to overcome manufacturing bottlenecks and optimize supply chains. Biogen Inc. and BioMarin Pharmaceutical Inc. concentrate on rare disease therapeutics, combining proprietary biologics with molecular targeting strategies. Eisai Co., Ltd. and Eli Lilly and Company drive innovation in neurology, particularly Alzheimer’s and Parkinson’s disease. Exelixis, Inc. and Genmab A/S explore combination regimens that integrate angiogenesis inhibitors with immunomodulators. F. Hoffmann-La Roche AG, Novartis AG and Pfizer Inc. maintain broad portfolios spanning small molecules to complex biologics, balancing branded leadership with generic competition. GlaxoSmithKline plc, Incyte Corporation and Sanofi S.A. fortify their presence in second-line therapies and adjuvant indications, aligning clinical development with emerging biomarker trends. Johnson & Johnson Services, Inc., Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. leverage robust R&D infrastructures to accelerate first-in-class candidates and integrate real-world data analytics for refined patient selection. As these organizations navigate patent cliffs and pricing pressures, strategic alliances and licensing agreements remain critical to sustaining innovation and securing market access across diverse regulatory landscapes.

Strategic Recommendations for Industry Leaders

To capitalize on emerging opportunities and mitigate evolving challenges, industry leaders should:
  • Invest in precision diagnostics and companion biomarkers to enhance patient stratification and accelerate regulatory approvals.
  • Diversify supply chains by fostering domestic manufacturing partnerships and leveraging contract development and manufacturing organizations to reduce tariff exposure.
  • Cultivate strategic alliances with academic institutions and technology firms to co-develop cell and gene therapies, addressing scale-up and quality control challenges.
  • Implement advanced analytics and artificial intelligence to optimize clinical trial design, monitor safety signals in real time and generate robust real-world evidence for payers.
  • Engage proactively with regulatory agencies and payers to shape favorable reimbursement frameworks, leveraging value-based pricing models and outcome-based contracts.
  • Prioritize patient-centric support programs, including digital health solutions and adherence initiatives, to improve retention and drive long-term therapy adoption.

Conclusion: Navigating the Future of Targeted Therapy

In conclusion, the targeted therapy landscape presents both unprecedented promise and complex challenges. Rapid advances in cell and gene therapies, immuno-oncology and precision medicine have redefined treatment paradigms across cardiology, neurology, oncology and rare diseases. Simultaneously, regulatory shifts, tariff-induced cost pressures and escalating competition from biosimilars and generics demand agile strategies. A nuanced understanding of segmentation dimensions-from therapy type and mechanism of action to end-user channels-enables more focused development and commercialization. Regional dynamics underscore the importance of tailored market access approaches, while leading companies demonstrate the critical role of collaboration in sustaining innovation. By integrating actionable recommendations that emphasize diagnostic precision, supply chain resilience, strategic partnerships and data-driven decision making, industry leaders can navigate the evolving environment to deliver superior patient outcomes and robust commercial performance. The path forward hinges on balancing scientific ambition with operational excellence and stakeholder engagement.

Market Segmentation & Coverage

This research report categorizes the Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Antibody-Drug Conjugates
  • Biosimilars
  • Cancer Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Cell Therapies
  • Gene Therapies
  • Hormonal Therapies
  • Monoclonal Antibodies
  • Small Molecules
  • Cardiology
    • Atherosclerosis
    • Heart Failure
  • Neurology
    • Alzheimer’s Disease
    • Parkinson's Disease
  • Oncology
    • Breast Cancer
    • Lung Cancer
    • Prostate Cancer
  • Rare Diseases
    • Cystic Fibrosis
    • Hemophilia
  • Branded
  • Generic
  • Adjuvant Therapy
  • Adjuvant Therapy
  • Neoadjuvant Therapy
  • Second-Line Therapy
  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals
  • Research Institutes
  • Angiogenesis Inhibitors
    • PDGFR Tyrosine Kinase Inhibitors
    • VEGFR Tyrosine Kinase Inhibitors
  • Immunomodulators
  • Kinase Inhibitors
  • Proteasome Inhibitors

This research report categorizes the Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Targeted Therapy Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Therapy Market, by Therapy Type
8.1. Introduction
8.2. Antibody-Drug Conjugates
8.3. Biosimilars
8.4. Cancer Vaccines
8.4.1. Preventive Vaccines
8.4.2. Therapeutic Vaccines
8.5. Cell Therapies
8.6. Gene Therapies
8.7. Hormonal Therapies
8.8. Monoclonal Antibodies
8.9. Small Molecules
9. Targeted Therapy Market, by Target Disease
9.1. Introduction
9.2. Cardiology
9.2.1. Atherosclerosis
9.2.2. Heart Failure
9.3. Neurology
9.3.1. Alzheimer’s Disease
9.3.2. Parkinson's Disease
9.4. Oncology
9.4.1. Breast Cancer
9.4.2. Lung Cancer
9.4.3. Prostate Cancer
9.5. Rare Diseases
9.5.1. Cystic Fibrosis
9.5.2. Hemophilia
10. Targeted Therapy Market, by Drug Type
10.1. Introduction
10.2. Branded
10.3. Generic
11. Targeted Therapy Market, by Therapeutic Application
11.1. Introduction
11.2. Adjuvant Therapy
11.3. Adjuvant Therapy
11.4. Neoadjuvant Therapy
11.5. Second-Line Therapy
12. Targeted Therapy Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Clinics
12.4. Hospitals
12.5. Research Institutes
13. Targeted Therapy Market, by Mechanism of Action
13.1. Introduction
13.2. Angiogenesis Inhibitors
13.2.1. PDGFR Tyrosine Kinase Inhibitors
13.2.2. VEGFR Tyrosine Kinase Inhibitors
13.3. Immunomodulators
13.4. Kinase Inhibitors
13.5. Proteasome Inhibitors
14. Americas Targeted Therapy Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Targeted Therapy Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Targeted Therapy Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Amgen Inc.
17.3.3. Astellas Pharma Inc.
17.3.4. AstraZeneca PLC
17.3.5. Bayer AG
17.3.6. BeiGene, Ltd.
17.3.7. Biogen Inc.
17.3.8. BioMarin Pharmaceutical Inc.
17.3.9. Bristol Myers Squibb Company
17.3.10. Eisai Co., Ltd.
17.3.11. Eli Lilly and Company
17.3.12. Exelixis, Inc.
17.3.13. F. Hoffmann-La Roche AG
17.3.14. Genmab A/S
17.3.15. Gilead Sciences, Inc.
17.3.16. GlaxoSmithKline plc
17.3.17. Incyte Corporation
17.3.18. Johnson & Johnson Services, Inc.
17.3.19. Merck & Co., Inc.
17.3.20. Merck KGaA
17.3.21. Novartis AG
17.3.22. Pfizer Inc.
17.3.23. Regeneron Pharmaceuticals, Inc.
17.3.24. Sanofi S.A.
17.3.25. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TARGETED THERAPY MARKET MULTI-CURRENCY
FIGURE 2. TARGETED THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. TARGETED THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TARGETED THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TARGETED THERAPY MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TARGETED THERAPY MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TARGETED THERAPY MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TARGETED THERAPY MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TARGETED THERAPY MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TARGETED THERAPY MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TARGETED THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TARGETED THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TARGETED THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TARGETED THERAPY MARKET SIZE, BY PDGFR TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TARGETED THERAPY MARKET SIZE, BY VEGFR TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. CANADA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 96. CANADA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 97. CANADA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 98. CANADA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 99. CANADA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 100. CANADA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 101. CANADA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 102. CANADA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. CANADA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 105. CANADA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 107. MEXICO TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 108. MEXICO TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 110. MEXICO TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 111. MEXICO TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 112. MEXICO TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. MEXICO TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. MEXICO TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 117. MEXICO TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. CHINA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 157. CHINA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 158. CHINA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 159. CHINA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 160. CHINA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 161. CHINA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 162. CHINA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 163. CHINA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 164. CHINA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. CHINA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. CHINA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 167. CHINA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. INDIA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 169. INDIA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 170. INDIA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 171. INDIA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 172. INDIA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 173. INDIA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 174. INDIA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 175. INDIA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. INDIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. INDIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. INDIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. INDIA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. JAPAN TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 193. JAPAN TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 194. JAPAN TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 195. JAPAN TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 196. JAPAN TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 197. JAPAN TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. JAPAN TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 199. JAPAN TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 200. JAPAN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. JAPAN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. JAPAN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 203. JAPAN TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 227. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 239. SINGAPORE TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 251. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 259. TAIWAN TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 260. TAIWAN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. TAIWAN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. TAIWAN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. TAIWAN TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. THAILAND TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 265. THAILAND TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 266. THAILAND TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 267. THAILAND TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 268. THAILAND TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 269. THAILAND TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 270. THAILAND TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 271. THAILAND TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 272. THAILAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. THAILAND TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. THAILAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 275. THAILAND TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 284. VIETNAM TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. VIETNAM TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. VIETNAM TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 287. VIETNAM TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 301. DENMARK TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 302. DENMARK TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 303. DENMARK TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 304. DENMARK TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 305. DENMARK TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 306. DENMARK TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 307. DENMARK TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 308. DENMARK TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 309. DENMARK TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. DENMARK TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. DENMARK TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 312. DENMARK TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 313. EGYPT TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 314. EGYPT TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 315. EGYPT TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 316. EGYPT TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 317. EGYPT TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 318. EGYPT TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 319. EGYPT TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 320. EGYPT TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 321. EGYPT TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 322. EGYPT TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. EGYPT TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 324. EGYPT TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 325. FINLAND TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 326. FINLAND TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 327. FINLAND TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 328. FINLAND TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 329. FINLAND TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 330. FINLAND TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 331. FINLAND TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 332. FINLAND TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 333. FINLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 334. FINLAND TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 335. FINLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 336. FINLAND TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 337. FRANCE TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 338. FRANCE TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 339. FRANCE TARGETED THERAPY MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 340. FRANCE TARGETED THERAPY MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 341. FRANCE TARGETED THERAPY MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 342. FRANCE TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 343. FRANCE TARGETED THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 344. FRANCE TARGETED THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 345. FRANCE TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 346. FRANCE TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 347. FRANCE TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 348. FRANCE TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2030 (USD MILLION)
TABLE 349. GERMANY TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 350. GERMANY TARGETED THERAPY MARKET SIZE, BY CANCER VACCINES, 2018-2030

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dual Targeted Therapy Market by Type, Application, End User, Drug Administration Route, Therapy Mechanism - Global Forecast 2025-2030 - Product Image

Dual Targeted Therapy Market by Type, Application, End User, Drug Administration Route, Therapy Mechanism - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030 - Product Image

Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030 - Product Image

Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030

  • Report
  • 100 Pages
  • Global
From
Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Biliary Tract Cancer Market (2024 Edition): Analysis By Indication (Extrahepatic Bile Duct Cancer, Intrahepatic Bile Duct Cancer), By Therapeutics, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Biliary Tract Cancer Market (2024 Edition): Analysis By Indication (Extrahepatic Bile Duct Cancer, Intrahepatic Bile Duct Cancer), By Therapeutics, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 218 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.